Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(USOTC:MBLTY)(PINK:MEOBF), announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission by its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 trial of the stem cell platform technology for treating patients with congestive heart failure.

More: continued here

This entry was posted on Tuesday, June 10th, 2008 at 1:06 pm and is filed under Stem Cell Research. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.